Veru provides fda update on request for emergency use authorization for sabizabulin for hospitalized covid-19 patients at high risk for ards

Miami, fl, march 02, 2023 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral ards-related diseases and for oncology, today announced that the u.s. food and drug administration (fda) has declined to grant at this time the company's request for emergency use authorization (eua) for sabizabulin, veru's novel microtubule disruptor, to treat hospitalized adult patients with moderate to severe covid-19 who are at high risk for acute respiratory distress syndrome (ards).
VERU Ratings Summary
VERU Quant Ranking